Acute myelogenous leukemia blasts as accessory cells during in vitro T lymphocyte activation

Cellular Immunology

Volumn 206, Issue 1, 2000, Pages 36-50

  Bruserud, Øystein ^a   Ulvestad, Elling ^a  

^a UNIVERSITY OF BERGEN   (Norway)

Author keywords

Acute myelogenous leukemia; Costimulation; Cytokine; T lymphocytes

Indexed keywords

B7 ANTIGEN; CD2 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 6; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MONOCLONAL ANTIBODY; PHYTOHEMAGGLUTININ; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CELL ACTIVATION; CELL ADHESION; CELL POPULATION; CLINICAL ARTICLE; CYTOKINE RELEASE; FEMALE; HUMAN; IMMUNOMODULATION; IRRADIATION; LYMPHOCYTE ACTIVATION; MALE; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0034493161     PISSN: 00088749     EISSN: None     Source Type: Journal    
DOI: 10.1006/cimm.2000.1725     Document Type: Article

References (51)

1. Intensive postremission chemotherapy in adults with acute myeloid leukaemia
2. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukaemia
3. A randomized study of high-dose cytarabine in induction in acute myeloid leukaemia
4. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukaemia in first remission
5. HLA-identical sibling bone marrow transplants vs chemotherapy for acute myelogenous leukaemia in first remission
6. Early allogeneic bone marrow transplantation favorably influences the outcome of adult patients suffering from acute myeloid leukaemia
7. Generation of leukaemia-specific T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukaemia
8. Immune surveillance in leukaemia: Rationale for immunotherapy?
9. Frequency of anti-recipient alloreactive T cell precursors in donor blood and graft versus host disease after HLA-identical sibling bone marrow transplantation
10. Correlation of minor histocompatibility antigen-specific cytotoxic T lymphocytes with graft versus host disease status and analysis of tissue distribution of their target antigens
11. Identical-twin bone marrow transplants for leukaemia
12. Graft versus leukaemia effect of donor lymphocyte transfusions in marrow grafted patients
13. Human CD4 T lymphocytes specifically recognize the fusion region of the hybrid protein pml/RARα present in acute promyelocytic leukemia cells
14. BCR/ABL leukaemia oncogen fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors
15. + T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide
16. Treatment of acute myeloid leukaemia patients with recombinant interleukin 2: A pilot study
17. Interleukin 2 may induce prolonged remission in advanced acute myelogenous leukaemia
18. Interleukin 2 and leukaemia
19. + memory T cells
20. Human T lymphocyte activation in the presence of acute myelogenous leukaemia blasts: Studies of allostimulated interferon-gamma secretion
21. Soluble factors produced by primary acute myeloid leukaemia cells inhibit Th1 cytokine production: Potential role of c-AMP dependent pathways
22. T lymphocyte functions in acute leukaemia patients with severe chemotherapy-induced cytopenia: Characterization of clonogenic T cell proliferation
23. Cellular immune responses in acute leukaemia patients with severe chemotherapy-induced leucopenia: Characterization of the cytokine repertoire of clonogenic cells
24. Acute myelogenous leukaemia blasts as accessory cells during T lymphocyte activation: Possible implications for future therapeutic strategies
25. Immunophenotypic patterns and cytogenetic anomalies in acute non-lymphocytic leukaemia subtypes: A prospective study of 432 patients
26. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T cell responses
27. + acute myeloid and lymphoid leukemia blasts can be induced to differentiate into dendritic cells
28. Identification of a malignant counterpart of the myelocyte-dendritic cell progenitor in an acute myeloid leukemia
29. Human acute myeloblastic leukemia cells differentiate in vitro into mature dendritic cells and induce the differentiation of cytotoxic T cells against autologous leukemias
30. Cytokine upregulation of the antigen presenting function of acute myeloid leukemia cells
31. Effects of interleukin 13 on cytokine secretion by human acute myelogenous leukaemia blasts
32. Effects of interleukin 10 on blast cells derived from patients with acute myelogenous leukaemia
33. Effects of γ-irradiation on acute myelogenous leukaemia blasts: In vitro studies of proliferation constitutive cytokine secretion and accessory cell function during T cell activation
34. IL2- and IL4-dependent proliferation of T cell clones derived early after allogeneic bone marrow transplantation: Studies of patients with chronic myelogenous leukaemia
35. Pre-B acute lymphoblastic leukaemia cells may induce T cell anergy to alloantigen
36. Mechanisms of growth factor expression in acute myeloid leukaemia (AML)
37. Effects of interferon alpha (IFN) on the expression of interleukin 1β, interleukin 6 (IL6), granulocyte-macrophage-colony stimulating factor (GM-CSF) and tumor necrosis factor α (TNF) in acute myeloid leukaemia (AML) blasts
38. Allogeneic bone marrow transplantation for acute non-lymphocytic leukaemia in first remission
39. Prognostic factors of patients with acute myeloid leukaemia (AML) allografted in first complete remission: An analysis of the EORTC-GIMEMA AML 8A trial
40. TCRζ chain in T cell development and selection
41. Functional studies with anti-CD3 heavy chain isotype switch-variant monoclonal antibodies. Accessory cell independent induction of interleukin 2 responsiveness in T cells by ε-anti-CD3
42. Different pathways of human T cell activation revealed by PHA-P and PHA-M
43. Expression of costimulatory molecules in human leukemias
44. Differential expression of adhesion molecules in acute leukaemia
45. The role of Fas/FasL in immunosuppression induced by human tumors
46. Production of Interleukin 2-containing growth medium for cloning of human T lymphocytes
47. IL 4, IL10 and IL13 in acute myelogenous leukaemia
48. Human Th1 and Th2 subsets: Doubt no more
49. Functional expression of Fas (CD95) in acute myeloid leukaemia cells in the context of CD34 and CD38 expression: Possible correlation with sensitivity to chemotherapy
50. Fas ligand is highly expressed by both normal hematopoietic progenitor cells and acute leukemic blasts
51. Escape from host-antitumor immunity